Outcome of patients older than 60 years with classical Hodgkin lymphoma treated with front line ABVD chemotherapy: Frequent pulmonary events suggest limiting the use of bleomycin in the elderly

British Journal of Haematology

Volumn 170, Issue 2, 2015, Pages 179-184

  Stamatoullas, Aspasia ^a   Brice, Pauline ^b   Bouabdallah, Reda ^c   Mareschal, Sylvain ^d   Camus, Vincent ^a   Rahal, Ilhem ^c   Franchi, Patricia ^b   Lanic, Hélène ^a   Tilly, Hervé ^a  

^a UNIVERSITÉ DE ROUEN   (France)

^b SAINT LOUIS HOSPITAL   (France)

^c INSTITUT PAOLI CALMETTES   (France)

^d CENTRE HENRI BECQUEREL   (France)

Author keywords

Doxorubicin, bleomycin, vinblastine and dacarbazine; Elderly; Hodgkin lymphoma; Pulmonary toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; BLEOMYCIN; DACARBAZINE; DOXORUBICIN; VINBLASTINE;

AGED; CANCER STAGING; CAUSE OF DEATH; COMPLICATION; FEMALE; HODGKIN DISEASE; HUMAN; LUNG INJURY; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BLEOMYCIN; CAUSE OF DEATH; DACARBAZINE; DOXORUBICIN; FEMALE; HODGKIN DISEASE; HUMANS; LUNG INJURY; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; VINBLASTINE;

EID: 84934435746     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.13419     Document Type: Article

References (26)

1. Azambuja, E., Fleck, J.F., Batista, R.G. & Menna Barreto, S.S. (2005) Bleomycin lung toxicity: who are the patients with increased risk? Pulmonary Pharmacology & Therapeutics, 18, 363-366.
2. Azoulay, E., Herigault, S., Levame, M., Brochard, L., Schlemmer, B., Harf, A. & Delclaux, C. (2003) Effect of granulocyte colony-stimulating factor on bleomycin-induced acute lung injury and pulmonary fibrosis. Critical Care Medicine, 31, 1442-1448.
3. Behringer, K., Goergen, H., Borchmann, P., Diehl, V., Fuchs, M., Hitz, F., Zijlstra, J.M., Greil, R., Markova, J., Topp, M.S., Soekler, M., Mathas, S., Meissner, J., von, Tresckow, B., Böll, B. & Engert, A. (2013) Impact of bleomycin and dacarbazine within the ABVD a regimenin the treatment of early-stage favorable Hodgkin Lymphoma: final a results of the GHSG HD13 trial. Haematologica 98 (Suppl. 2), 11, Abstract T033
4. Boll, B., Bredenfeld, H., Gorgen, H., Halbsguth, T., Eich, H.T., Soekler, M., Markova, J., Keller, U., Graeven, U., Kremers, S., Geissler, M., Trenn, G., Fuchs, M., von, Tresckow, B., Eichenauer, D.A., Borchmann, P. & Engert, A. (2011) Phase 2 study of PVAG (prednisone, vinblastine, doxorubicin, gemcitabine) in elderly patients with early unfavorable or advanced stage Hodgkin lymphoma. Blood, 118, 6292-6298.
5. Boll, B., Gorgen, H., Fuchs, M., Pluetschow, A., Eich, H.T., Bargetzi, M.J., Weidmann, E., Junghanss, C., Greil, R., Scherpe, A., Schmalz, O., Eichenauer, D.A., von, Tresckow, B., Rothe, A., Diehl, V., Engert, A. & Borchmann, P. (2013) ABVD in older patients with early-stage Hodgkin lymphoma treated within the German Hodgkin Study Group HD10 and HD11 trials. Journal of Clinical Oncology, 31, 1522-1529.
6. Borchmann, P., Diehl, V., Goergen, H., Lohri, A., Zijlstra, J., Topp, M., Fuchs, M., Eich, H. & Engert, A. (2010) Dacarbazine is an essential component of ABVD in the treatment of early favourable Hodgkin Lymphoma: results of the second interim analysis of the GHSG HD13 trial. Haematologica, 95(Suppl. 2), 473, abs. 1146
7. Canellos, G.P., Anderson, J.R., Propert, K.J., Nissen, N., Cooper, M.R., Henderson, E.S., Green, M.R., Gottlieb, A. & Peterson, B.A. (1992) Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. The New England Journal of Medicine, 327, 1478-1484.
8. Charlson, M.E., Pompei, P. & MacKenzie, C.R. (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. Journal of Chronic Diseases, 40, 373-383.
9. Cheson, B.D., Horning, S.J., Coiffier, B., Shipp, M.A., Fisher, R.I., Connors, J.M., Lister, T.A., Vose, J., Grillo-Lopez, A., Hagenbeek, A., Cabanillas, F., Klippensten, D., Hiddemann, W., Castellino, R., Harris, N.L., Armitage, J.O., Carter, W., Hoppe, R. & Canellos, G.P. (1999) Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. Journal of Clinical Oncology, 17, 1244-1253.
10. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V. (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
11. Eghbali, H., Raemaekers, J., Carde, P., EORTC Lymphoma Group. (2005) The EORTC strategy in the treatment of Hodgkin's lymphomas. European Journal of Haematology, 66(suppl.), 135-140.
12. Engert, A., Ballova, V., Haverkamp, H., Pfistner, B., Josting, A., Duhmke, E., Muller-Hermelink, K. & Diehl, V. (2005) Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. Journal of Clinical Oncology, 23, 5052-5060.
13. Evens, A.M., Helenowski, I., Ramsdale, E., Nabhan, C., Karmali, R., Hanson, B., Parsons, B., Smith, S., Larsen, A., McKoy, J.M., Jovanovic, B., Gregory, S., Gordon, L.I. & Smith, S.M. (2012) A retrospective multicenter analysis of elderly Hodgkin lymphoma: outcomes and prognostic factors in the modern era. Blood, 119, 692-695.
14. Evens, A.M., Hong, F., Gordon, L.I., Fisher, R.I., Bartlett, N.L., Connors, J.M., Gascoyne, R.D., Wagner, H., Gospodarowicz, M., Cheson, B.D., Stiff, P.J., Advani, R., Miller, T.P., Hoppe, R.T., Kahl, B.S. & Horning, S.J. (2013) The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496. British Journal of Haematology, 161, 76-86.
15. Halbsguth, T.V., Nogova, L., Mueller, H., Sieniawski, M., Eichenauer, D.A., Schober, T., Nisters-Backes, H., Borchmann, P., Diehl, V., Engert, A. & Josting, A. (2010) Phase 2 study of BACOPP (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) in older patients with Hodgkin lymphoma: a report from the German Hodgkin Study Group (GHSG). Blood, 116, 2026-2032.
16. Hasenclever, D. & Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. New England Journal of Medicine, 339, 1506-1514.
17. Ho, P., Sherman, P. & Grigg, A. (2012) Intermittent granulocyte colony-stimulating factor maintains dose intensity after ABVD therapy complicated by neutropenia. European Journal of Haematology, 88, 416-421.
18. Kaplan, E.L. & Meier, P. (1958) Nonparametric estimation from incomplete observations. Journal of American Statistical Association, 53, 457-481.
19. Kolstad, A., Nome, O., Delabie, J., Lauritzsen, G.F., Fossa, A. & Holte, H. (2007) Standard CHOP-21 as first line therapy for elderly patients with Hodgkin's lymphoma. Leukaemia & Lymphoma, 48, 570-576.
20. Levis, A, Anselmo, AP, Ambrosetti, A, Adamo, F, Bertini, M, Cavalieri, E, Gavarotti, P, Genua, A, Liberati, M, Pavone, V, Pietrasanta, D, Ricetti, MM, Scalabrini, DR, Salvi, F, Vitolo, U, Angelucci, E, Boccadoro, M, Gallo, E & Mandelli, F; Intergruppo Italiano Linfomi (IIL). (2004) VEPEMB in elderly Hodgkin's lymphoma patients. Results from an Intergruppo Italiano Linfomi (IIL) study. Annals of Oncology, 15, 123-128.
21. Proctor, S.J., Wilkinson, J. & Sieniawski, M. (2009) Hodgkin lymphoma in the elderly: a clinical review of treatment and outcome, past, present and future. Critical Reviews in Oncology Hematology, 71, 222-232.
22. Proctor, S.J., Wilkinson, J., Jones, G., Watson, G.C., Lucraft, H.H., Mainou-Fowler, T., Culligan, D., Galloway, M.J., Wood, K.M., McNally, R.J., James, P.W. & Goodlad, J.R. (2012) Evaluation of treatment outcome in 175 patients with Hodgkin lymphoma aged 60 years or over: the SHIELD study. Blood, 119, 6005-6015.
23. Sjoberg, J., Halthur, C., Kristinsson, S.Y., Landgren, O., Nygell, U.A., Dickman, P.W. & Bjorkholm, M. (2012) Progress in Hodgkin lymphoma: a population-based study on patients diagnosed in Sweden from 1973-2009. Blood, 119, 990-996.
24. Soubeyran, P., Bellera, C.A., Gregoire, F., Blanc, J., Ceccaldi, J., Blanc-Bisson, C., Mertens, C., Mathoulin-Pélissier, S., Fonck, M. & Rainfray, M. (2008) Validation of a screening test for elderly patients in oncology. Journal of Clinical Oncology, 26, 20568.
25. Viviani, S., Zinzani, P.L., Rambaldi, A., Brusamolino, E., Levis, A., Bonfante, V., Vitolo, U., Pulsoni, A., Liberati, A.M., Specchia, G., Valagussa, P., Rossi, A., Zaja, F., Pogliani, E.M., Pregno, P., Gotti, M., Gallamini, A., Rota, S.D., Bonadonna, G. & Gianni, A.M. (2011) ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned. The New England Journal of Medicine, 365, 203-212.
26. Younes, A., Bartlett, N.L., Leonard, J.P., Kennedy, D.A., Lynch, C.M., Sievers, E.L. & Forero-Torres, A. (2010) Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. The New England Journal of Medicine, 363, 1812-1821.